WIN-MTB-2024002 - WIN International Molecular Tumor Board: A 52-year-old female with unmeasurable Stage IIIc colon cancer. (PubMed, Oncotarget) - Oct 17, 2026 - "Despite surgical resection and adjuvant treatment which included FOLFOX, FOLFIRI with bevacizumab and local radiation, the patient's disease was difficult to track due to small, non-FDG-avid lymph nodes in the aortocaval region and persistent circulating tumor DNA (ctDNA). Following a review by an international Molecular Tumor Board (MTB), maintenance therapy options were discussed, including the personalized combinations of regorafenib, sulindac, and metformin, or fruquintinib, sulindac, and metformin, based on the patient's molecular alterations...In the event of relapse, the MTB recommended the combination of regorafenib, sulindac, and metformin, with the addition of trametinib and ivosidenib. The combination of regorafenib, ipilimumab, and nivolumab (RIN) was also considered due to the patient's high PD-L1 expression. Further clinical trial options, such as pan-RAF inhibitors, NK cell agonists, and TAS-102 with bevacizumab, were also..."
Biomarker • IO biomarker • Journal • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • APC • FLT1 • FLT4 • IDH1 • KRAS • PD-L1 • TP53
|
|
Alberto Hernando-Calvo; Amal Al-Omari; Arjun Oberoi; Catherine Bresson; Fanny Wunder; Hikmat Abdel-Razeq; Rachel Elsey; Razelle Kurzrock; Sadakatsu Ikeda; Shai Magidi; Susana Aguilar Izquierdo; Tobias Meissner; Wafik S El-Deiry; Zhihuang Hu
|